"If you are currently or recently hospitalized, recovering from surgery, or being treated for cancer, you are at increased risk of developing serious and potentially deadly blood clots. This condition, called healthcare-associated venous thromboem"...
Accidental overdosage of INNOHEP® (tinzaparin sodium injection) may lead to bleeding complications (see WARNINGS, Hemorrhage). Nosebleeds, blood in urine or tarry stools may be noted as the first signs of bleeding. Easy bruising or petechial hemorrhages may precede frank bleeding. In case of minor bleeding, the patient should be monitored for signs of more severe bleeding.
Of patients known to have received an overdose of tinzaparin sodium in clinical trials, defined as one or more doses > 200 IU/kg for the treatment of DVT or > 100 IU/kg for the prevention of DVT, approximately 16% experienced a bleeding complication.
Of spontaneous reports of probable overdosing with tinzaparin sodium, approximately 81% were accompanied by bleeding, usually hematoma. Most patients who have bleeding complications while receiving INNOHEP® (tinzaparin) can be controlled by discontinuing INNOHEP® (tinzaparin) , applying pressure to the site, if possible, and replacing volume and hemostatic blood elements (e.g., red blood cells, fresh frozen plasma, platelets) as required. In the event that this is ineffective, protamine sulfate can be administered.
In cases of serious bleeding or large overdose, protamine sulfate (1% solution) can be given by slow IV infusion at a dose of 1 mg protamine for every 100 anti-Xa IU of INNOHEP® (tinzaparin) given. A second infusion of 0.5 mg protamine sulfate per 100 anti-Xa IU of INNOHEP® (tinzaparin) may be administered if the aPTT measured 2 to 4 hours after the first infusion remains prolonged. Even with the additional dose of protamine, the aPTT may remain more prolonged than would usually be found following administration of protamine to reverse unfractionated heparin. Protamine does not completely neutralize tinzaparin sodium anti-Xa activity (maximum about 60%).
Particular care should be taken to avoid overdosage with protamine sulfate. Administration of protamine sulfate can cause severe hypotensive and anaphylactoid reactions. Because fatal reactions have been reported with protamine sulfate, it should be given only when resuscitation facilities are readily available. For additional information consult the labeling of Protamine Sulfate Injection, USP, products.
Single SC doses of tinzaparin sodium at 22,000 and 7,700 IU/kg (about 10 and 7 times the maximum recommended human dose, respectively, based upon body surface area) were lethal to mice and rats, respectively. Symptoms of acute toxicity included hematoma formation and bleeding at the injection site, anemia, decreased motor activity, unsteady gait, piloerection, and ptosis.
INNOHEP® (tinzaparin) is contraindicated in patients with active major bleeding, in patients with (or history of) heparin-induced thrombocytopenia, or in patients with hypersensitivity to tinzaparin sodium.
Patients with known hypersensitivity to heparin, sulfites, benzyl alcohol, or pork products should not be treated with INNOHEP® (tinzaparin) .This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 11/8/2010
Additional Innohep Information
Innohep - User Reviews
Innohep User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.